ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer

MLA

Sara A Hurvitz, et al. “ASTEFANIA: Adjuvant Ado-Trastuzumab Emtansine and Atezolizumab for High-Risk, HER2-Positive Breast Cancer.” Future Oncology (London, England), vol. 18, no. 32, Nov. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3773f1e4c79e44fa384522db0d66280e&authtype=sso&custid=ns315887.

APA

Sara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, Nadia Harbeck, Sherene Loi, Yeon Hee Park, Aleix Prat, Leslie Gilham, Thomas Boulet, Nino Gochitashvili, Estefania Monturus, Chiara Lambertini, Beatrice Nyawira, Adam Knott, Eleonora Restuccia, & Peter Schmid. (2022). ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncology (London, England), 18(32).

Chicago

Sara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, Nadia Harbeck, Sherene Loi, Yeon Hee Park, Aleix Prat, et al. 2022. “ASTEFANIA: Adjuvant Ado-Trastuzumab Emtansine and Atezolizumab for High-Risk, HER2-Positive Breast Cancer.” Future Oncology (London, England) 18 (32). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3773f1e4c79e44fa384522db0d66280e&authtype=sso&custid=ns315887.